2025-523340-12-00招募中1 期
Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2025年12月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Project leader
Scientific
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent HypertensionAdvanced Lung CancerNCT07261098Shanghai Chest Hospital200
招募中
不适用
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerGastric NeoplasmsBile Duct CancerPancreas CancerCholangiocarcinomaColorectal NeoplasmsNCT01915225National Cancer Institute (NCI)1,800
招募中
Unknown
Autologous Vax-NK/HCC Consolidation Therapy in Patients with Extensive Stage Small Cell Lung CancerNeoplasmsKCT0008301Chonnam National University Hospital Hwasun Hospital12
招募中
不适用
molecular based analysis and novel therapies development of chronic myelocytic leukemiachronic myelocytic leukemiaJPRN-UMIN000015409Keio University School of Medicine, Division of Hematology200
已完成
不适用
A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent NeuroblastomaRefractory NeuroblastomaRelapsed NeuroblastomaNCT01109238Giselle Sholler5